BIONXT SOLUTIONS ACQUIRES NOVEL PRECISION DRUG COATING AND DELIVERY TECHNOLOGY
Mar 7, 2023
VANCOUVER, BC – March 07, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
BIONXT SIGNS CLINICAL STUDY AGREEMENT AND COMMENCES MANUFACTURE OF CLINICAL SAMPLES FOR STUDY OF TRANSDERMAL ROTIGOTINE PATCH FOR PARKINSON’S DISEASE
Mar 1, 2023
VANCOUVER, BC – March 1, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
BIONXT REPORTS UPDATE ON COMMERCIALIZATION OF ROTIGOTINE PATCH FOR TREATMENT OF PARKINSON’S DISEASE
Feb 13, 2023
VANCOUVER, BC – February 13, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
XPhyto reports excellent Rotigotine in-vitro/ex-vivo results for Parkinson’s disease treatment
Oct 18, 2022
Vancouver, Canada, and Uttenweiler, Germany (October 18, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...
XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study
Oct 11, 2022
Vancouver, Canada, and Uttenweiler, Germany (October 11, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...
XPhyto adds pharmaceutical manufacturing expert Dr. Florian A. Sahr to its European team
Jun 8, 2022
Vancouver, Canada, and Uttenweiler, Germany (June 8, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...
XPhyto reports product developments on platform-based Rotigotine transdermal patch for Parkinson’s disease
May 9, 2022
Vancouver, Canada, and Uttenweiler, Germany (May 9, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...
XPhyto reports market and product developments on platform-based Rotigotine transdermal patch for Parkinson’s disease
Apr 4, 2022
Vancouver, Canada, and Uttenweiler, Germany (April 4, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...
XPhyto Epilepsy clinical trial planned in 2022 with its proprietary fast-dissolving CBD oral strips
Dec 15, 2021
Vancouver, Canada, and Uttenweiler, Germany (December 15, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...
XPhyto Reports Development Update for its Drug Delivery Business
Oct 12, 2021
Rotigotine transdermal skin patch optimization and pivotal study planning underwayRotigotine patch manufacturing, sales and marketing in preparationCannabinoid oral dissolvable film (ODF) programs advanced, CBD ODF...
XPhyto Provides Update on Drug Formulation and Development Business
May 13, 2021
Rotigotine transdermal human pilot study successfully completed; program advancing to pivotal studyLand purchased for construction of commercial drug manufacturing facility in Germany Vancouver, Canada, and...
XPhyto Announces Drug Formulation Strategy And 2021 Milestones
Jan 28, 2021
Construction of commercial drug manufacturing facility in GermanyFour clinical studies in neurological indications in 2021Development of oral biosensor and contract development & manufacturingPsychedelic transdermal and...
